Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

Figure 1

The analysis of progression-free survival (PFS) between different groups. (a) Platelet (PLT); (b) lactate dehydrogenase (LDH); (c) different treatment regimens; (d) absolute count of CD8⁺CD28⁻ T cell.

(a)

(b)

(c)

(d)